Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Express Scripts
Dow
McKinsey

Last Updated: June 29, 2022

Investigational Drug Information for GDC-0349


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for GDC-0349?

GDC-0349 is an investigational drug.

There have been 184 clinical trials for GDC-0349. The most recent clinical trial was a Phase 3 trial, which was initiated on January 8th 2013.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are twenty-six US patents protecting this investigational drug and two hundred and twenty-four international patents.

Recent Clinical Trials for GDC-0349
TitleSponsorPhase
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1
Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaNational Cancer Institute (NCI)Phase 1/Phase 2
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLKazia Therapeutics LimitedPhase 2

See all GDC-0349 clinical trials

Clinical Trial Summary for GDC-0349

Top disease conditions for GDC-0349
Top clinical trial sponsors for GDC-0349

See all GDC-0349 clinical trials

US Patents for GDC-0349

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0349 See Plans and Pricing Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN) See Plans and Pricing
GDC-0349 See Plans and Pricing mTORC1 inhibitors The Regents of the University of California (Oakland, CA) See Plans and Pricing
GDC-0349 See Plans and Pricing Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) See Plans and Pricing
GDC-0349 See Plans and Pricing 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions SABILA BIOSCIENCES LLC (New City, NY) See Plans and Pricing
GDC-0349 See Plans and Pricing Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (South San Francisco, CA) See Plans and Pricing
GDC-0349 See Plans and Pricing Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN) See Plans and Pricing
GDC-0349 See Plans and Pricing Quinolone derivatives as FGFR inhibitors Principia Biopharma, Inc. (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GDC-0349

Drugname Country Document Number Estimated Expiration Related US Patent
GDC-0349 Australia AU2016232923 2035-03-19 See Plans and Pricing
GDC-0349 Australia AU2017286654 2035-03-19 See Plans and Pricing
GDC-0349 Australia AU2020277128 2035-03-19 See Plans and Pricing
GDC-0349 Brazil BR112017019790 2035-03-19 See Plans and Pricing
GDC-0349 Canada CA2980016 2035-03-19 See Plans and Pricing
GDC-0349 Canada CA3027506 2035-03-19 See Plans and Pricing
GDC-0349 China CN106146508 2035-03-19 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Express Scripts
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.